Difference between revisions of "Carfilzomib (Kyprolis)"
m (→References) |
m |
||
| Line 19: | Line 19: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
*7/20/2012: Received accelerated approval for the treatment of patients with [[Multiple myeloma|multiple myeloma]] who have received at least two prior therapies including [[Bortezomib (Velcade)|bortezomib]] and an [http://hemonc.org/wiki/Category:Immunomodulatory_drugs_(IMiDs) immunomodulatory agent] and have demonstrated disease progression on or within 60 days of completion of the last therapy | *7/20/2012: Received accelerated approval for the treatment of patients with [[Multiple myeloma|multiple myeloma]] who have received at least two prior therapies including [[Bortezomib (Velcade)|bortezomib]] and an [http://hemonc.org/wiki/Category:Immunomodulatory_drugs_(IMiDs) immunomodulatory agent] and have demonstrated disease progression on or within 60 days of completion of the last therapy | ||
| + | |||
| + | ==Post-marketing concerns== | ||
| + | *January 2015: New safety information concerning posterior reversible encephalopathy syndrome (PRES), based on several case reports<ref>[http://jco.ascopubs.org/content/early/2014/05/05/JCO.2013.49.6166.full.pdf Xuemei Cai and Shamik Bhattacharyya et al. 2014]</ref><ref>[http://austinpublishinggroup.com/hematology/download.php?file=fulltext/hematology-v2-id1018.pdf James Pauff et al. 2015]</ref>. | ||
==Also known as== | ==Also known as== | ||
Revision as of 20:49, 26 February 2015
General information
Class/mechanism: Second-generation proteasome inhibitor that interferes with degradation of ubiquitinated proteins by binding irreversibly to the 20S proteasome, which is the proteolytic core particle inside the 26S proteasome. This disrupts normal homeostatic mechanisms, leading to impaired tumor proliferation, apoptosis/cell death.[1][2][3][4][5]
Route: IV
Extravasation: no information
NDC: NDC 76075-101-01; NDC 76075-0101-01
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Brief patient counseling information is available on pages 21-22 of the Carfilzomib (Kyprolis) package insert.[1]
- Carfilzomib (Kyprolis) patient drug information (Chemocare)[6]
- Carfilzomib (Kyprolis) patient drug information (UpToDate)[7]
History of changes in FDA indication
- 7/20/2012: Received accelerated approval for the treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy
Post-marketing concerns
- January 2015: New safety information concerning posterior reversible encephalopathy syndrome (PRES), based on several case reports[8][9].
Also known as
Precise Name: carfilzomib (RXCUI 1302966)
CFZ or PR-171.
References
- ↑ 1.0 1.1 1.2 Carfilzomib (Kyprolis) package insert
- ↑ Carfilzomib (Kyprolis) package insert (locally hosted backup)
- ↑ Kyprolis manufacturer's website
- ↑ Kyprolis 7/20/2012 FDA approval press release
- ↑ Carfilzomib (Kyprolis) manufacturer's clinical development website
- ↑ Carfilzomib (Kyprolis) patient drug information (Chemocare)
- ↑ Carfilzomib (Kyprolis) patient drug information (UpToDate)
- ↑ Xuemei Cai and Shamik Bhattacharyya et al. 2014
- ↑ James Pauff et al. 2015